Successful rapid desensitization for cetuximab-induced anaphylaxis
Allergy, Asthma & Respiratory Disease
; : 294-296, 2015.
Article
Dans Ko
| WPRIM
| ID: wpr-83768
Responsable en Bibliothèque :
WPRO
ABSTRACT
Cetuximab, a chimeric mouse-human immunoglobulin, is an antiepidermal growth factor receptor monoclonal antibody. It has been approved by the U.S. Food and Drug Administration for the treatment of metastatic colorectal and head/neck cancer, but can cause fatal hypersensitivity reactions in some patients. A 66-year-old male with metastatic sigmoid cancer had cetuximab-induced anaphylaxis when the first dose of cetuximab was administered. Cetuximab was safely readministered for another 15 cycles based on the rapid desensitization protocol. We experienced a case of cetuximab-induced anaphylaxis on the first exposure which was successfully managed by rapid desensitization.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Tumeurs du sigmoïde
/
Food and Drug Administration (USA)
/
Immunoglobulines
/
Désensibilisation immunologique
/
Cétuximab
/
Hypersensibilité
/
Anaphylaxie
Type d'étude:
Guideline
Limites du sujet:
Aged
/
Humans
/
Male
langue:
Ko
Texte intégral:
Allergy, Asthma & Respiratory Disease
Année:
2015
Type:
Article